- Personalis Inc (NASDAQ:PSNL) and Moderna Inc (NASDAQ:MRNA) have signed a new agreement to continue using the Personalis NeXT Platform as part of upcoming clinical studies of mRNA-4157/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck & Co Inc (NYSE:MRK).
- The platform, also utilized in the vaccine candidate’s Phase 2b study, will be used to sequence genomic information from a patient’s tumor sample to identify the unique genetic mutations that are most likely to generate a tailored antitumor response.
- In January, Personalis approved a reduction in its workforce by up to approximately 30% to reduce operating costs and improve operating efficiency.
- The company estimates that it will incur charges of approximately $3 million for severance payments and employee benefits, primarily in the first quarter of 2023.
- Price Action: PSNL shares are up 26.80% at $3.86 on the last check Friday.
Immutep Announces Site Expansion For INSIGHT-003 Phase I Trial
Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the INSIGHT-003
